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Background: Recent evidence suggests that nutritional interventions may improve muscle outcomes in
malnutrition and sarcopenia.
Objectives: We evaluated the effects of 2 high-quality oral nutritional supplements (ONS) differing in
amount and type of key nutrients in older adult men and women.
Design: A multicenter, randomized, double-blinded, controlled clinical trial.
Participants: Malnourished and sarcopenic men and women, 65 years and older (n ¼ 330).
Intervention:A24-week interventionperiodwith2 energy-rich (330kcal) ONStreatment groups: Control ONS
(CONS, 14 g protein; 147 IU vitamin D3) versus Experimental ONS (EONS, 20 g protein; 499 IU vitamin D3; 1.5 g
CaHMB) takentwicedaily.BothONSalsocontainedothervitamins,minerals,andnutrients invaryingamounts.
Measurements: Isokinetic peak torque (PT, Nm) leg strength, grip strength (kg), and gait speed (m$s1)
were assessed at baseline and 12 and 24 weeks. Left and right leg muscle mass (LMM, kg) were assessed by
dual-energy x-ray absorptiometry (DXA). Muscle quality (MQ) was leg strength expressed relative to the
tested LMM (Nm$kg1). Subgroup analyses were performed: severe sarcopenia (low skeletal mass index,
low grip strength [<30 kg men; <20 kg women], low gait speed [<0.8 m$s1]) and mild-moderate sar-
copenia (low skeletal mass index, normal gait speed, or normal grip strength).
Results: Both ONS groups (EONS and CONS) improved PT, MQ, grip strength, and gait speed from baseline
with no treatment differences. Those with severe sarcopenia (44%) exhibited lower baseline PT and MQ,
with no differences in strength improvements between treatments. However, participants with mild-
moderate sarcopenia exhibited higher baseline PT and MQ, with differences in strength improvements
at 12 weeks (EONS > CONS, P ¼ .032) in those with normal grip strength. There were no treatment dif-
ferences based on sarcopenic severity for either grip strength or gait speed.
Conclusion: ONS improved strength outcomes in malnourished older adults with sarcopenia. In those
with mild-moderate sarcopenia, but not severe sarcopenia, consumption of the EONS improved leg
muscle strength and quality compared with the standard CONS.
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J.T. Cramer et al. / JAMDA 17 (2016) 1044e1055 1045Malnutrition and sarcopenia are conditions that are common and
overlapping in older adults.1 Both conditions are strongly inﬂuenced
by nutrition, where an inadequate nutrient intake is a contributing
factor to weight loss and consequently functional impairment. Low
lean body mass, a characteristic of sarcopenia, has recently been
included in the deﬁnition of malnutrition.2 Another characteristic of
sarcopenia, reduced muscle strength, also has been suggested as an
indicator of nutritional status.3 Malnutrition and sarcopenia inde-
pendently contribute to an increased risk of adverse outcomes, such as
falls,4,5 physical disability,6 poor quality of life,7,8 and increased mor-
tality.9e11 Therefore, interventions for older adults that address both
malnutrition and sarcopenia may help reduce these negative out-
comes and prolong an older adult’s independent lifestyle and improve
the quality of life.
The beneﬁts of nutritional interventions for malnutrition-related
outcomes are unequivocal.12 However, the impact of nutrition on
sarcopenia is less certain. Most studies report the effects of short-term
nutritional interventions on muscle protein synthesis, whereas there
are very few high-quality randomized controlled trials.13 A recent
review of the prevalence of sarcopenia and interventions to treat it by
the International Sarcopenia Initiative13 concluded that muscle func-
tion impairments in older adults can be improved by exercise in-
terventions, whereas the effects of protein supplementation alone
were inconsistent. The authors indicated, however, that calcium b-
hydroxy b-methylbutyrate (CaHMB), a metabolite of leucine, showed
promise,13 which was also consistent with a recent meta-analysis
examining the beneﬁts of CaHMB on preserving muscle mass in
older adults.14
The overall expert recommendation was that “Further studies
are needed to determine the effect of different nutrition in-
terventions on muscle mass and function using robust, multi-centre
and standardised approaches with single or complex nutrition
interventions and clinically relevant outcomes (muscle strength,
physical performance).”13p757
The anabolic signaling of amino acids in skeletal muscle is thought
to be primarily triggered by the consumption of essential amino acids,
particularly the branched chain amino acid leucine.15,16 It has been
shown that higher amounts of protein are needed in older adults
compared with young adults to stimulate muscle protein synthesis
due to the anabolic resistance of aging muscle.17 Thus, it has been
recommended that older adults need at least 1.0 to 1.2 g$kg1$d1,
which is greater than the current US Recommended Dietary Allow-
ance of 0.8 g$kg1$d1, to maintain muscle function.18 Because HMB is
derived exclusively from leucine in the body,19 and both leucine and
HMB have been shown to stimulate muscle protein synthesis and
attenuate muscle protein breakdown,16 many of the beneﬁcial effects
of leucine may be mediated, in part, by HMB.
A recent pilot study20 demonstrated that the consumption of 3 g
CaHMB daily for 24 weeks positively inﬂuenced both leg strength and
muscle quality (MQ) in healthy older men and women compared with
a placebo. These ﬁndings suggested that CaHMB may improve clini-
cally relevant strength parameters associated with the loss of func-
tionality and performance. Despite some earlier limited evidence in
healthy older adults,21e23 it remains unclear whether the magnitude
of these effects would be similar or greater for older adults with a
combination of malnutrition and sarcopenia, who present elevated
risks of morbidity and mortality.5,6,10
Vitamin D3 supplementation is widely recognized to improve bone
health, postural stability, and prevent falls and fractures leading to
disability.24,25 Supplementation is especially relevant to older men
and women, due to a combination of malnutrition, reduced sunlight
exposure, and a decrease in synthesis capacity of skin.24 Current sci-
entiﬁc opinion is 800 IU (20 mg) of vitamin D from all sources should
be consumed daily to prevent falls in men and women older than
60 years.25Older adults with malnutrition and sarcopenia may not consume
sufﬁcient amounts of high-quality protein and/or other nutrients
through diet alone. Finding a convenient and compliant nutritional
strategy for the attenuation of both malnutrition and sarcopenia
would be advantageous. Oral nutritional supplements (ONS) are
ideally suited to provide high-quality nutrition when diet alone is
insufﬁcient to meet nutritional needs. Furthermore, because of their
energy, protein, and vitamin density, supplementing an older adult’s
diet with an ONS should not reduce the typical dietary intake, but
should improve body weight and several functional outcomes, such as
hand grip strength.3,26 To that end, the purpose of this study was to
evaluate the effects of 2 high-quality ONS differing in amount and type
of key nutrients in older adult men and women with combined
malnutrition and sarcopenia.
Methods
Research Design
This was a 24-week, prospective, randomized, double-blinded,
controlled, 2-treatment parallel study design. Men and women
65 years and older from 8 countries across Europe and North America
with both malnutrition and sarcopenia were enrolled. Malnutrition
was deﬁned as a Subjective Global Assessment rating of B or C.27 Sar-
copenia was deﬁned as low grip strength (<20 kg women; <30 kg
men) and/or low gait speed (<0.8 m$s1) in conjunction with low
skeletal mass index.28 Enrolled individuals were stratiﬁed for gender
and age at each study site and randomized into ONS treatment groups:
(1) Control ONS (CONS) and (2) Experimental ONS (EONS). The protocol
was reviewedby local ethics committees or institutional reviewboards
and all participants signed awritten informed consent. This study was
a registered on ClinicalTrials.gov with the identiﬁer: NCT01191125.
Participants were instructed to drink 2 servings of the ONS daily
between regular meals throughout the duration of the study. Partici-
pants also were instructed to continue their usual diet, physical ac-
tivity, and lifestyle habits, with the following exceptions: (1)
consumption of study product daily and (2) the recommended ad
libitum diet contained aminimum of 0.8 g protein per kg bodyweight.
Study participants visited the research facility at baseline (week 0)
and every 6 weeks (1 week) thereafter until the end of the 24-week
intervention. At each visit, study staff reviewed product intake forms
to assess compliance, dietary intake, recorded medication changes,
and adverse events. Fasting blood draw, height (measured only at
baseline, m), weight (calibrated stadium scale, kg), body composition,
leg strength, grip strength, and gait speed tests were conducted at
baseline and at 12 and 24 weeks.
To reduce the potential for learning effects, each participant visited
the laboratory for 2 familiarization trials before the baseline assess-
ment (separated by at least 1 day within 4 days before baseline) and 1
familiarization trial 4 days before both the 12- and 24-week as-
sessments to practice the strength and functionality tests. Finally, all
study staff were trained ﬁrst by webinar and second in person by a
single investigator (JTC) on how to perform the body composition,
strength, and functionality tests according to standardized testing
protocols.
Study Products
Ready-to-drink 220-mL ONSs were packaged indistinguishably
except for a 5-digit code to maintain the double-blind study design.
Products were isocaloric, providing 330 kcal per serving (Table 1). Each
serving of the CONS (Ensure Plus; Abbott, Zwolle, Netherlands) con-
tained 14 g protein, 11 g fat, 44 g carbohydrate, 147 IU vitamin D3, and
additional vitamins and minerals. Each serving of the EONS provided
20 g protein,11 g fat, 36 g carbohydrate,1.5 g CaHMB, 499 IU vitamin D3,
Table 1
Approximate Compositions of Control (CONS) and Experimental (EONS) Products
Ingredient Unit CONS
220 mL
EONS
220 mL
Protein g 14 20
Fat g 11 11
Carbohydrate g 44 36
CaHMB g 0 1.5
Fructooligosaccharide g 0 1.7
Carnitine mg 0s 40
Vitamin A (Palmitate) mg RE 194 132
Vitamin A (Palmitate) IU 642 440
Vitamin A (B-Carotene) mg RE 64 132
Vitamin A (B-Carotene) IU 642 1320
Vitamin D3 mg 3.7 12
Vitamin D3 IU 147 499
Vitamin E mg a TE 5.3 5.5
Vitamin E IU 7.9 8.1
Vitamin K1 mg 26 33
Vitamin C mg 26 35
Folic Acid mg 73 77
Vitamin B1 mg 0.44 0.57
Vitamin B2 mg 0.59 0.75
Vitamin B6 mg 0.59 0.75
Vitamin B12 mg 1.4 1.3
Niacin equivalent mg 5.7 6.6
Pantothenic acid mg 2.4 2.4
Biotin mg 13 13
Choline mg 121 154
Sodium mg 264 242
Potassium mg 440 616
Chloride mg 242 139
Calcium mg 257 352
Phosphorus mg 202 209
Magnesium mg 66 55
Iron mg 4.6 4.6
Zinc mg 3.5 3.9
Manganese mg 1.1 1.1
Copper mg 396 539
Iodine mg 48 48
Selenium mg 18 20
Chromium mg 17 19
Molybdenum mg 35 33
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(Table 1). Product intake was recorded by participants on daily product
intake forms that were reviewed with site staff at each visit.
Leg Strength
Maximal voluntary isokinetic peak torque (PT) for the leg exten-
sion exercisewasmeasured at 60$s1. A standardized testing protocol
was used as previously described29 with 2 familiarization trials before
the baseline assessment and 1 familiarization trial before the 12- and
24-week assessments. All measurements were performed using cali-
brated isokinetic dynamometers (site models included Biodex; Biodex
Medical Inc, Shirley, NY, Cybex; Cybex International, Inc, Ronkonkoma,
NY, KinCom; Chattanooga Group, Hixson, TN, and TechnoGym; Tech-
noGym SpA, Gambet-Tola, Forli, Italy) that tested the dominant leg
determined by kicking preference; however, if the dominant leg was
unable to perform the isokinetic strength tests for any reason, the
contralateral leg was used. Each participant performed 3 consecutive,
maximal, voluntary, isokinetic leg extension muscle actions at 60$s1
(1.05 rad$s1). The average PT across the 3 repetitions was used as the
representative value expressed in Newton-meters (Nm) measured at
baseline and 12 and 24 weeks.
Grip Strength
Grip strength was measured with a calibrated dynamometer (Jamar
hydraulic hand dynamometer; Patterson Medical, Warrenville, IL)adjusted to the appropriate grip width.30,31 Participants were asked to
squeeze the dynamometer handle as quickly and forcefully as possible
with the dominant hand according to previously described proced-
ures.32,33 Each participant completed 3 trials, and the average of the trials
was analyzed as the ﬁnal grip strength value expressed in kilograms.
Gait Speed
Gait speed (s) was measured by timing the participant’s ability to
walk 4 m at a normal pace.34 Each participant performed the gait
speed assessment twice, with the faster of the 2 times used as the
representative score. A score of <0.8 m$s1 (5.0 s during 4 m) was
used to identify participants with low gait speed.28
To be enrolled in this study, either participants’ grip strength
values must have been<20 kg for women and<30 kg for men, and/or
gait speed scores must have been <0.8 m$s1 28 during the screening
visit (before the ﬁrst familiarization visit). Participants were naive to
the grip strength and gait speed cutoffs for inclusion at the time of
screening. Subsequent grip strength and gait speed scores were
measured after the familiarization visits at baseline and 12 and
24 weeks. Incidentally, 11% (n ¼ 37) of the participants’ grip strength
values and gait speed scores at baseline marginally exceeded the
cutoffs that had originally beenmet at the screening visit. However, all
participants fell below the sarcopenia cutoffs at baseline from the
initial dual-energy x-ray absorptiometry (DXA) measurements
(described in the following section).
Body Composition
DXA was used to measure body composition with whole-body,
supine DXA scans (site models included GE Lunar Prodigy Advance;
GE Lunar Prodigy Pro or Primo; GE DPX Pro, Bravo, or Duo; General
Electric [GE] Healthcare, Madison, WI; or Hologic Discovery A;
Hologic, Inc, Bedford, MA). All DXA scans were standardized to a
common phantom and sent to an independent laboratory for analysis
(Body Composition Analysis Center, Gerald J. and Dorothy R. Friedman
School of Nutrition Science and Policy, Tufts University, Boston, MA).
Measurements queried from the independent laboratory at baseline
included whole-body fat mass (FM, kg), regional appendicular lean
soft tissue (ALST, kg; used only for calculating sarcopenia inclusion
criteria), leg muscle mass (LMM, kg) as the sum of both the left and
right leg muscle mass values, and tested leg muscle mass (TLMM, kg)
representing the leg used for the strength testing.
Baseline DXA scans were used to classify participants with sarco-
penia based on the following procedure. First, ALST was considered
the sum of lean soft tissue mass from both the right and left arms and
legs, which were deﬁned by computer-generated and manually
adjusted regions of interest (established by the independent labora-
tory) separating the appendages from the trunk and head. Second,
total body skeletal muscle (kg) was calculated according to the
equation validated by Kim et al,35 in which for sex, men ¼ 1 and
women ¼ 0, and age is expressed in years:
TBSM ¼ ð1:13 ALSTÞ  ð0:02 ageÞ þ ð0:61 sexÞ þ 0:97
Third, the relative skeletal mass index (RSMI, %) was calculated
with the equation adapted from Janssen et al,36 inwhich body mass
is expressed in kilograms:
RSMI ¼ ðTBSMObody massÞ  100
Fourth, the absolute skeletal mass index (SMI, kg$m2) was
calculated according to the equation of Baumgartner et al,37 in
which height is expressed in meters:
SMI ¼ ALSTO

height2

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according to the equations of Newman et al,38 in which FM is total
body FM expressed in kilograms and height is expressed in meters:
ALM for men ¼ 22:48þ ð24:14 heightÞ þ ð0:21 FMÞ
ALM for women ¼ 13:19þ ð14:75 heightÞ þ ð0:23 FMÞ
Finally, participants were deﬁned as sarcopenic at baseline if
their values fell below any 1 of 4 cutoff models: (1) RSMI  28% for
women or  37% for men,36 (2) SMI < 5.45 kg$m2 for women
or < 7.26 kg$m2 for men,37 (3) SMI < 5.67 kg$m2 for women
or < 7.25 kg$m2 for men,39 or (4) ALM < 1.73 kg for women
or < 2.29 for men.38n = 800 men and w
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MQ (Nm$kg1) was calculated as PT relative to the TLMM. The
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previously as an indicator of muscle function.20,40Sarcopenia Severity Classiﬁcations
Sarcopenia severity was evaluated in participants with low skeletal
mass according to baseline grip strength and gait speed cutoffs as
follows28: (1) Severe sarcopenia included participants with both
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Table 2
Baseline Characteristics of Study Subjects
CONS Group
n ¼ 165
EONS Group
n ¼ 165
Age, y 77 (71, 81) 77 (71, 81)
Gender, % women 62% 62%
Weight, kg 70 (60, 78) 68 (58, 78)
BMI, kg$m2 26 (24, 29) 25 (23, 29)
Leg strength, Nm 57 (37, 77) 56 (37, 73)
Grip strength, kg 19 (15, 26) 19 (15, 27)
Gait speed, m$s1 0.8 (0.7, 0.9) 0.7 (0.6, 0.9)
FM, kg 25 (20, 30) 25 (18, 30)
LMM, kg* 12 (10, 15) 12 (10, 14)
RSMI, % 25 (23, 31) 26 (23, 30)
MQ, Nm$kg1 9.1 (7.0, 12.1) 9.2 (6.7, 12.4)
Daily energy intake, kcal$d1 1620 (1257, 2012) 1627 (1253, 1971)
Daily protein intake, g$kg1$d1 0.97 (0.73, 1.30) 0.94 (0.70, 1.20)
Serum vitamin D, nmol$L1 60 (40, 78) 65 (45, 85)
Values are percentages or median (25th, 75th IQR). There were no signiﬁcant dif-
ferences (P > .05) between groups at baseline.
*LMM data represent the sum of left and right LMMs acquired from the DXA.
Table 3
Baseline Leg Strength, Grip Strength, and Gait Speed in Sarcopenia Severity
Classiﬁcations
CONS Group EONS Group
Severe sarcopenia n ¼ 64 n ¼ 80
Leg strength, Nm 50 (31, 64) 48 (31, 62)
Grip strength, kg 16 (12, 19) 17 (14, 20)
Gait speed, m$s1 0.68 (0.59, 0.73) 0.66 (0.58, 0.74)
MQ, Nm$kg1 8.8 (6.0, 11.7) 8.3 (5.6, 11.2)
Sarcopenia* n ¼ 101 n ¼ 83
Leg strength, Nm 62 (46, 88) .0006 64 (45, 81)<.0001
Grip strength, kg 23 (18, 30)<.0001 23 (18, 33)<.0001
Gait speed, m$s1 0.84 (0.79, 0.95)<.001 0.87 (0.79, 0.97)<.0001
MQ, Nm$kg1 10.0 (7.6, 12.1)ns .059 10.6 (7.8, 13.2).0019
Sarcopenia, normal
gait*,y
n ¼ 75 n ¼ 61
Leg strength, Nm 61 (46, 82) .0051 60 (41, 75) .0051
Grip strength, kg 20 (17, 26) <.0001 19 (15, 28) .0014
Gait speed, m$s1 0.91 (0.82, 1.0)<.0001 0.93 (0.84, 1.0) <.0001
MQ, Nm$kg1 9.6 (7.3, 12.0) ns 9.1 (7.4, 12.8) .034
Sarcopenia, normal
grip*,y
n ¼ 46 n ¼ 39
Leg strength, Nm 71 (54, 98) <.0001 76 (59, 111) <.0001
Grip strength, kg 31 (23, 35) <.0001 33 (26, 36) <.0001
Gait speed, m$s1 0.78 (0.67, 0.87)<.0001 0.76 (0.68, 0.89) <.0001
MQ, Nm$kg1 11.2 (8.6, 12.4).007 11.3 (9.1, 13.5) .0002
Values are medians (25th, 75th IQR). Superscript P values are compared with the
severe sarcopenia group. Two participants were missing grip strength or gait speed
assessments at baseline.
*Despite meeting inclusion criteria during the screening process, 37 participants
recorded both normal grip strength and gait speed at baseline.
yThirty-seven participants appear in both subgroups.
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sarcopenia. Because sarcopenia is deﬁned by the European Working
Group on Sarcopenia in Older People (EWGSOP)28 as having either
impaired gait speed (normal grip) or impaired grip strength (normal
gait), these participants were further subcategorized: (3) sarcopenia
with normal gait were participants with normal gait speed
(0.8 m$s1); and (4) sarcopenia with normal grip were participants
with normal grip strength (20 kg [women]; 30 kg [men]).
Dietary Instruction and Assessment
Participants were provided dietary education and instruction on
methods to increase their habitual protein intake to a minimum of
0.8 g protein per kg body weight per day (g$kg1$d1). Participants
were given 3-day dietary logs to record their food intake. Three-day
dietary records were recorded from a sample of 2 weekdays and 1
weekend day. Records were reviewed and entered into food compo-
sition analysis programs (such as the US Department of Agriculture’s
(USDA) SuperTracker, www.supertracker.usda.gov; USDA National
Nutrient Database for Standard Reference, http://ndb.nal.usda.gov)
used to estimate daily energy intake (kcal$d1) and daily protein
intake (g$kg1$d1) as an average of the 3 days. If protein intake was
less than 0.8 g$kg1$d1, dietary instructions on methods to increase
protein intake were given and reinforced.
Vitamin D
Samples of blood drawn from a superﬁcial vein were sent to a
commercial laboratory (ICON Central Laboratories, Inc., Farmingdale,
NY) for analysis of serum 25-OH vitamin D (nmol$l1) at baseline and
12 and 24 weeks.
Statistical Analyses
This study was powered to detect an effect size of 0.56 for PT based
on a difference between groups of 5.65 Nm (SD¼ 10.11 Nm) as well as
to allow for the detection of an effect size of 0.44 for the secondary
variable, LMM, based on a difference between groups of 0.19 kg
(SD ¼ 0.43 kg). Assuming an alpha level of P  .05 with a 2-tailed test
and power of 0.80, the required sample sizes were n ¼ 52 and n ¼ 82
per group for PT and LMM, respectively. Therefore, the study was
designed with a planned enrollment of n¼ 150 participants per group
to allow for up to 45% attrition.
The primary outcome variable in this studywas established a priori
as change in PT, whereas the secondary outcome variables were
weight, LMM, TLMM, grip strength, gait speed, and product compli-
ance. Therefore, change from baseline at 12 and 24 weeks for all
variables were analyzed. Baseline and change values were expressed
as median 25th and 75th interquartile ranges (IQR), because many,
but not all, variables were non-normally distributed based on the
presence of non-normal residual distributions. Consequently,
nonparametric analyses were used. The Wilcoxon rank sum test was
used for between-group analyses, and the Wilcoxon signed rank test
(nonparametric equivalent to the paired t-test) was used for the
within-group analyses. Data were analyzed and presented as ITT. SAS
versions 9.1.3 and 9.2 (SAS, Inc., Cary, NC) were used for all statistical
analyses. An alpha level of P  .05 was considered statistically signif-
icant for all comparisons.
Results
Participants
A total of 800 men and women were evaluated for eligibility
(Figure 1), and malnutrition was conﬁrmed in 80%. At least 1measure of strength or physical performance was impaired in 76%.
Within this group, sarcopenia was further observed in 75%. A total of
330 of these men and women were enrolled into the study, of which
88% completed the study in the CONS group and 79% in the EONS
group.
Baseline characteristics are shown in Table 2. There were no dif-
ferences between groups at baseline. The median age at enrollment
was 77 years, and most were women (62%). With one exception, all
participants exhibited a Subjective Global Assessment (SGA) rating of
“B” (mild to moderate malnourishment); one in the EONS group had
an SGA rating of “C” (severe malnourishment). All participants had a
low skeletal muscle mass (ie, low RSMI, SMI, or ALM), which classi-
ﬁed them as sarcopenic,28 whereas the median body mass index
(BMI) of 26 kg$m2 indicated that most were not underweight.
Subjects in the CONS and EONS groups were well-matched in FM and
LMM.
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There were no differences between groups in PT at baseline (me-
dian [25th, 75th IQR] ¼ 57 [37, 77] Nm for CONS; 56 [37, 73] Nm for
EONS) (Table 2). At 12 weeks, PT increased from baseline in both groups
(2 [3, 9] Nm for CONS, P < .001; 3 [1, 10] Nm for EONS, P < .001),
which was maintained throughout the 24 weeks (2 [3, 10] Nm for
CONS, P < .001; 4 [4, 8] Nm for EONS; P < .001), with no differences
between treatments.
Table 2 shows PT values at baseline, Table 3 shows PT values at
baseline separated by sarcopenia severity classiﬁcation, and30
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penia and normal grip strength increased PT from baseline to
24 weeks (P < .05), although this increase was not quite statisti-
cally greater than the CONS treatment (Figure 3D, P ¼ .06). Inter-
estingly, the increases in PT observed in the EONS group from
baseline to 12 weeks appeared to be maintained in the sarcopenia
normal grip strength subgroup at 24 weeks, but not in the CONS
group (Figure 3D). The severe sarcopenia group also showed an
improvement from baseline in PT at 24 weeks with the EONS
treatment (Figure 3D).
Grip Strength
Grip strength improved from baseline to 12 weeks, which was
maintained through the 24-week period in both treatment groups
(P < .001). The observed changes across both treatment groups and
all sarcopenia severity classiﬁcations ranged from 0.50 to 0.83 kg at
12 weeks and 0.25 to 1.33 kg at 24 weeks. Both the severe sarco-
penia and sarcopenia with normal gait speed groups increased grip
strength at 12 and 24 weeks with no treatment differences observed
(Table 4); however, the single exception was in the sarcopenia
group with normal gait speed, in which the increase was not sta-
tistically signiﬁcant at 12 weeks in the EONS treatment group
(Table 4).Gait Speed
Gait speed improved from baseline to 12 weeks and baseline to
24 weeks in both treatment groups. The observed changes across both
treatment groups and all sarcopenia severity classiﬁcations ranged
from 0.01 to 0.05 m$s1 at 12 weeks and 0.03 to 0.08 m$s1 at
24 weeks (P < .05). Both the severe sarcopenia and sarcopenia with
normal grip strength groups increased gait speed at 12 and 24 weeks
with no treatment differences observed (Table 4).
Body Composition
Table 5 summarizes the baseline values, and Table 6 shows the
changes from baseline for BMI, body weight, FM, LMM, and TLMM for
the sarcopenia severity classiﬁcations. BMI, body weight, and FM
increased from baseline in all sarcopenia severity classiﬁcations at
both 12 and 24 weeks (Table 6). There were no differences between
treatments (except in the sarcopenia group with normal gait speed, in
which the change from baseline to 12 weeks in BMI and body weight
were greater for CONS compared to EONS). There were no changes in
LMM or TLMM across the 24-week study, except LMM at 12 weeks in
CONS participants with severe sarcopenia, but this was not maintained
at 24 weeks or was this observed in TLMM. There were no treatment
differences for LMM or TLMM.
Table 4
Changes from Baseline in Grip Strength and Gait Speed for Sarcopenia Severity
Classiﬁcations
Sarcopenia
Severity
Visit CONS Group EONS Group
Severe sarcopenia
Grip strength,
kg
12 wk 0.83 (0.67, 2.00) .0077 0.68 (0.50, 2.17) .002
24 wk 1.33 (0.33, 3.0) <.0001 0.67 (0.0, 2.8) <.0001
Gait speed,
m$s1
12 wks 0.04 (0.02, 0.13) .0006 0.03 (0.01, 0.11) .0022
24 wks 0.06 (0.02, 0.15) <.0001 0.04 (0.01, 0.11) .0003
Sarcopenia*
Grip strength,
kg
12 wk 0.67 (0.67, 2.33) .004 0.67 (0.67, 2.33) .03
24 wk 0.67 (0.83, 3.00) .02 1.33 (0.17, 3.5) .001
Gait speed,
m$s1
12 wk 0.02 (0.04, 0.10) .006 0.01 (0.05, 0.08)
24 wk 0.02 (0.03, 0.11) .04 0.05 (0.04, 0.15) .002
Sarcopenia, normal gait speed*,y
Grip strength,
kg
12 wk 0.83 (0.67, 2.67) .0057 0.50 (0.67, 2.33)
24 wk 0.67 (0.95, 3.33) .0212 1.33 (0.33, 3.50) .0084
Gait speed,
m$s1
12 wk 0.02 (0.04, 0.09) 0.01 (0.08, 0.08)
24 wk 0.01 (0.07, 0.10) 0.04 (0.06, 0.14)
Sarcopenia, normal grip strength*,y
Grip strength,
kg
12 wk 0.50 (1.13, 2.50) 0.83 (2.00, 3.00)
24 wk 0.25 (1.62, 1.32) 1.18 (2.17, 2.67)
Gait speed,
m$s1
12 wk 0.05 (0.01, 0.12) .003 0.05 (0.0, 0.10) .032
24 wk 0.06 (0.02, 0.11) .0017 0.07 (0.02, 0.17) .0007
Values are median change scores (25th, 75th IQR). Superscript P values indicate
changes from baseline.
*Despite meeting inclusion criteria during the screening process, 37 participants
recorded both normal grip strength and gait speed at baseline.
yThirty-seven participants appear in both subgroups.
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Table 2 shows MQ values at baseline, and Table 3 shows baseline
MQ values separated by sarcopenia severity classiﬁcation. Figures 2C,
3C, and 3F show the changes in MQ at 12 and 24 weeks for all theTable 5
Baseline Body Composition for Sarcopenia Severity Classiﬁcations
CONS Group EONS Group
Severe sarcopenia n ¼ 64 n ¼ 80
BMI, kg$m2 28 (25, 30) 27 (23, 29)
Body weight, kg 69 (59, 78) 69 (57, 76)
FM, kg 27 (22, 32) 25 (18, 31)
LMM, kg* 11 (9, 13) 11 (10, 14)
TLMM, kgy 5.4 (4.8, 6.6) 5.7 (5.1, 6.9)
Sarcopeniaz n ¼ 101 n ¼ 83
BMI, kg$m2 26 (23, 28).003 25 (23, 29)
Body weight, kg 70 (62, 77) 68 (60, 80)
FM, kg 24 (18, 28).026 25 (19, 28)
LMM, kg* 13 (11, 16).0026 13 (10, 16).014
TLMM, kgy 6.4 (5.3, 8.1).002 6.3 (5.3, 8.0).011
Sarcopenia, normal gait speedz,x n ¼ 75 n ¼ 61
BMI, kg$m2 25 (23, 28).002 24 (23, 28)
Body weight, kg 68 (59, 76) 64 (57, 77)
FM, kg 23 (18, 28).018 24 (18, 28)
LMM, kg* 12 (10, 16)<.01 12 (10, 14)
TLMM, kgy 6.2 (5.3, 8.1).008 6.2 (5.2, 7.3)
Sarcopenia, normal grip strengthz,x n ¼ 46 n ¼ 39
BMI, kg$m2 26 (24, 29) 27 (23, 30)
Body weight, kg 75 (67, 80).045 77 (64, 87).002
FM, kg 25 (18, 30) 26 (21, 32)
LMM, kg* 14 (11, 16)<.001 14 (12, 17)<.0001
TLMM, kgy 6.9 (5.7, 8.2)<.001 6.9 (5.9, 9.0)<.0001
Values are medians (25th, 75th IQR). Superscript P values are compared with the
severe sarcopenia group.
*LMM data represent the sum of left and right legs muscle masses acquired from
the DXA.
yTLMM data represent the single LMM acquired from the DXA corresponding to
the leg used during the strength testing.
zDespite meeting inclusion criteria during the screening process, 37 participants
recorded both normal grip strength and gait speed at baseline.
xThirty-seven participants appear in both subgroups.sarcopenia severity classiﬁcations. Those with severe sarcopenia had
the lowest MQ at baseline compared with the sarcopenia groups with
normal gait speed or normal grip strength (Table 3, P< .05), except for
thosewith normal gait speed in the CONS group. Thosewith sarcopenia
and normal grip strength in the EONS group improved MQ to a greater
extent (P ¼ .027) than those in the CONS group from baseline to
12 weeks (Figure 3C), but the treatment difference at 24weeks did not
reach statistical signiﬁcance (Figure 3F, P ¼ .07). A similar ﬁnding was
observed during the ﬁrst 12 weeks for those with sarcopenia and
normal gait speed in the EONS group, although the treatment effect did
not reach statistical signiﬁcance (Figure 3C, P ¼ .08). Like PT after
24 weeks, the improvements in MQwere largely sustained in the EONS
group, whereas those with sarcopenia and normal grip strength in the
CONS group showed an attenuated ability to maintain the changes in
MQ (Figure 3F). At 24 weeks, the severe sarcopenia group appeared to
beneﬁt from both interventions.
Compliance and Dietary Intake
Treatment compliance was calculated as a percentage of actual
consumption divided by expected consumption over the 24-week
period. Compliance in the CONS group was 88% (median intake 2.0
[1.7, 2.0]) servings$d1 and 86% (1.9 [1.5, 2.0]) servings$d1 in the EONS
group.
Dietary intakes of energy, protein, and serum vitamin D at baseline
and 12 and 24 weeks are shown in Figure 4. Baseline energy intake
(kcal$d1), protein intake (g$kg1$d1), and serum vitamin D
(nmol$l1) were similar in CONS and EONS groups. As expected due to
high compliance, both groups increased energy intake and protein
intake by 12 weeks, which was maintained through 24 weeks with
differences between treatments at both time points for protein intake
(Figures 4D and 4E, respectively). Furthermore, as expected due to
high compliance, both groups increased serum vitamin D at 12 and
24 weeks from baseline with a treatment difference (EONS > CONS) at
12 and 24 weeks (Figure 4F).
Adverse Events
The highest percentage of participant-reported adverse events
(AEs) and/or serious adverse events (SAEs) was associated with the
gastrointestinal system with n ¼ 47 (28.5%) in the EONS group and
n ¼ 53 (32.5%) in the CONS group. Most of these were assessed as
probably or possibly related to study product. There were no statis-
tically signiﬁcant differences between treatment groups for AEs or
SAEs. Two participants in the EONS group died as a result of SAEs for
infections; neither event was related to the study product as deter-
mined by the site physicians.
Discussion
Themain ﬁnding from this study was that in men andwomenwith
malnutrition and sarcopenia, supplementation with high-quality ONS
improved the primary outcome variable of leg strength assessed as PT.
Improvements in PT were observed at both 12 and 24 weeks
compared with baseline in both groups with no treatment differences
between groups. Compliance was high, as demonstrated by increases
in protein intake and vitamin D levels. Based on the EWGSOP sug-
gestion28 to incorporate the conceptual staging of sarcopenia, post hoc
analyses were carried out on severe and mild-moderate sarcopenia
subgroups. These analyses indicated that men andwomenwith severe
sarcopenia were more physically and functionally compromised than
those with mild-moderate sarcopenia. Therefore, further subgroup
analyses were performed to determine if sarcopenia staging28 may
differentially affect leg strength responses to the nutritional
interventions.
Table 6
Changes from Baseline in Body Composition for Sarcopenia Severity Classiﬁcations
Sarcopenia Severity
Classiﬁcation
Visit CONS Group EONS Group P Values for
Between-Group
Treatment Effects
Severe sarcopenia n ¼ 64 n ¼ 80
BMI, kg$m2 12 wk 0.8 (0.3, 1.4) <.0001 0.7 (0.3, 1.1) <.0001 d
24 wk 1.0 (0.2, 2.0) <.0001 0.8 (0.0, 1.6) <.0001 d
Body weight, kg 12 wk 2.0 (0.8, 3.1) <.0001 2.0 (0.7, 3.0)<.0001 d
24 wk 2.7 (0.5, 4.5) <.0001 2.0 (0.1, 4.1) <.0001 d
FM, kg 12 wk 1.7 (0.8, 2.9) <.0001 1.5 (0.7, 2.2) <.0001 d
24 wk 2.4 (1.0, 3.4) <.0001 1.8 (0.0, 3.1) <.0001 d
LMM, kg* 12 wk 0.14 (0.10, 0.41).026 0.08 (0.26, 0.54) d
24 wk 0.10 (0.32, 0.57) 0.10 (0.31, 0.46) d
TLMM, kgy 12 wk 0.07 (0.14, 0.23) 0.00 (0.24, 0.25) d
24 wk 0.05 (0.18, 0.40) 0.02 (0.21, 0.20) d
Sarcopeniaz n ¼ 101 n ¼ 83
BMI, kg$m2 12 wk 0.8 (0.3, 1.2) <.0001 0.5 (0.0, 1.1) <.0001 d
24 wk 0.9 (0.2, 1.3) <.0001 0.7 (0.1, 1.4) <.0001 d
Body weight, kg 12 wk 2.0 (0.9, 3.2) <.0001 1.4 (0.0, 2.9) <.0001 d
24 wk 2.5 (0.7, 3.6) <.0001 1.9 (0.4, 4.0) <.0001 d
FM, kg 12 wk 1.3 (0.3, 2.4) <.0001 1.1 (0.4, 2.0) <.0001 d
24 wk 2.2 (0.5, 3.8) <.0001 1.9 (0.9, 2.8) <.0001 d
LMM, kg* 12 wk 0.05 (0.36, 0.56) 0.05 (0.28, 0.29) d
24 wk 0.08 (0.39, 0.40) 0.06 (0.27, 0.39) d
TLMM, kgy 12 wk 0.10 (0.16, 0.24) 0.01 (0.20, 0.25) d
24 wk 0.05 (0.25, 0.21) 0.04 (0.13, 0.21) d
Sarcopenia, normal gait speedz,x
BMI, kg$m2 12 wk 0.8 (0.3, 1.2) <.0001 0.4 (0.0, 1.0) <.0001 .042
24 wk 0.9 (0.2, 1.3) <.0001 0.7 (0.2, 1.3) <.0001 d
Body weight, kg 12 wk 2.0 (0.9, 3.3) <.0001 1.2 (0.0, 2.9) <.0001 .032
24 wk 2.5 (0.5, 3.6) <.0001 1.8 (0.5, 4.0) <.0001 d
FM, kg 12 wk 1.4 (0.3, 2.5) <.0001 1.1 (0.3, 1.9) <.0001 d
24 wk 2.2 (0.5, 3.9) <.0001 1.9 (0.9, 2.6) <.0001 d
LMM, kg* 12 wk 0.04 (0.37, 0.46) 0.05 (0.30, 0.36) d
24 wk 0.10 (0.41, 0.37) 0.02 (0.30, 0.39) d
TLMM, kgy 12 wk 0.03 (0.19, 0.20) 0.01 (0.22, 0.26) d
24 wk 0.04 (0.24, 0.18) 0.03 (0.12, 0.21) d
Sarcopenia, normal grip strengthz,x
BMI, kg$m2 12 wk 0.8 (0.3, 1.1) <.0001 0.7 (0.1, 1.1) <.0001 d
24 wk 0.8 (0.4, 1.2) <.0001 1.2 (0.0, 1.6) <.0001 d
Body weight, kg 12 wk 2.2 (0.8, 3.1) <.0001 2.3 (0.3, 3.2) <.0001 d
24 wk 2.3 (1.3, 3.5) <.0001 3.2 (0.1, 4.6) <.0001 d
FM, kg 12 wk 1.3 (0.6, 2.3) <.0001 1.1 (0.4, 2.6) <.0001 d
24 wk 2.0 (0.2, 3.8) <.0001 1.9 (0.9, 3.4) <.0001 d
LMM, kg* 12 wk 0.22 (0.50, 0.64) 0.07 (0.28, 0.30) d
24 wk 0.01 (0.24, 0.51) 0.15 (e0.22, 0.46) d
TLMM, kgy 12 wk 0.11 (0.14, 0.29) 0.01 (0.18, 0.27) d
24 wk 0.04 (0.26, 0.23) 0.07 (0.13, 0.27) d
Values are median change scores (25th, 75th IQR). Superscript P values represent changes from baseline. Dashes indicate that the P-value for that particular between-group
treatment effect was greater than 0.05.
*LMM data represent the sum of left and right legs muscle masses acquired from the DXA.
yTLMM data represent the single leg muscle mass acquired from the DXA corresponding to the leg used during the strength testing.
zDespite meeting inclusion criteria during the screening process, 37 participants recorded both normal grip strength and gait speed at baseline.
xThirty-seven participants appear in both subgroups.
J.T. Cramer et al. / JAMDA 17 (2016) 1044e10551052Based on previous literature in malnutrition, an improvement in
muscle strength in response to ONS was expected.41e44 Differences in
responses to the EONS between sarcopenia subgroups were notable.
Early beneﬁts in leg strength (at 12 weeks) were observed in men and
women with mild-moderate sarcopenia who consumed the EONS
compared with those who consumed the CONS. This was not observed
in the severe sarcopenia subgroup. In the mild-moderate sarcopenia
subgroups, the increases in PT in response to EONS were higher than
responses to the CONS group. At 24 weeks, the severe sarcopenia
subgroup did demonstrate improvements in leg strength above
baseline, which may have reﬂected a delayed time course in skeletal
muscle adaptations45,46 that may extend with more severe muscle
dysfunction. Incidentally, physical and morphological differences be-
tween the sarcopenia staging subgroups may explain the differential
responses to the ONS intervention. For example, the severe sarcopenia
subgroup displayed lower baseline LMM, PT, MQ, grip strength, gait
speed, and higher FM than the mild-moderate sarcopenia groups(Figure 2, Tables 2 and 4). This may have been due to a more
compromised status, which has been associated with inﬂammation
and metabolic and vascular dysfunction.47,48 These can negatively
affect the responses of muscle to nutritional input and could explain
the observed differences among the severe and mild-moderate sar-
copenic subgroups to the ONS interventions.
The importance of baseline physical characteristics was further
emphasized by the Sarcopenia Project of the Foundation for the Na-
tional Institutes of Health,49 which reported a pooled analysis of data
from 4 randomized trials of various interventions in older women. The
results showed that adaptations in muscle function and strength were
dependent on the participants’ baseline grip strength. Although the
interventions varied, baseline muscle strength was able to differen-
tiate the responses to sarcopenia interventions. Likewise, the results of
the present study supported the authors’ conclusions49 that muscle
weakness, deﬁned by grip strength, is able to differentiate responses
to the ONS intervention, and suggests that sarcopenia staging should
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Fig. 4. Left column: Median (25%, 75% IQR) for (A) energy intake (kcal$d1), (B) protein intake (g$kg1$d1), and (C) serum vitamin D (nmol$l1) at baseline and 12 and 24 weeks.
Right column: Median (25%, 75% IQR) for (C) energy intake (kcal$d1), (D) protein intake (g$kg1$d1), and (E) serum vitamin D (nmol$l1) change from baseline at 12 and 24 weeks.
For (A), (B), and (C), solid line ¼ CONS; dashed line ¼ EONS. For (D), (E), and (F), Gray ¼ CONS; Black ¼ EONS. Symbols represent signiﬁcant changes from baseline. *P < .05, yP < .01,
zP < .0001. P values represent signiﬁcant differences between treatment groups.
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participants enrolled in the current study were categorized as having
severe sarcopenia, its prevalence using EWGSOP criteria in other
groups with malnutrition or chronic disease is unknown. Dam
et al.,50 reevaluated sarcopenia data using EWGSOP criteria frommore
than 10,000 adults older than 65 years and reported prevalence of
sarcopenia was 5.3% and 13.3%, in men and women, respectively,
whereas the prevalence of severe sarcopeniawas 0.7% inmen and 2.9%
in women. Cruz-Jentoft et al13 reported the prevalence of sarcopenia
in patients in long-term care ranged from 14% to 33% (2 studies) and
was 10% in a single study of hospitalized patients; however, data on
severe sarcopenia in the clinical groups were unavailable, as not all
groups made the distinction.
Previous studies have demonstrated that older adults may expe-
rience anabolic resistance15 due, in part, to impaired blood ﬂow and
the subsequent limited amino acid delivery to the muscle.51e53 Tim-
merman et al47 reported that a prior bout of aerobic exercise increased
the anabolic effects of nutrient consumption in older adults by
improving the nutrient-signaled vasodilation and subsequent nutrient
delivery to the muscle. The authors47 deﬁned the importance of
nutritive ﬂow by suggesting that muscle blood ﬂow is an important
factor for the delivery of nutrients (amino acids) to themuscle in order
for the nutrients to have an anabolic effect. In the present study, the
subgroup that beneﬁted the most from the EONS were those who were
mild-moderately sarcopenic with normal grip strength (impaired
gait). This subgroup also displayed the highest baseline leg strength(Table 3). Normal grip and high leg strength indirectly suggested that
blood ﬂow to the large quadriceps femoris muscles governing leg
strength may have been more viable for this group, which also may
explain why this group experienced the largest improvements in PT
and MQ from baseline to 12 weeks while consuming the anabolic
nutrient-rich EONS. Greater nutritive ﬂow to the muscle would, in
theory, deliver greater amounts of all nutrients to the muscle,
resulting in greater gains in muscle strength. In contrast, the severe
sarcopenia group had lower leg strength, which may have indirectly
indicated poorer leg muscle blood ﬂow, and in turn, less anabolic
response from the EONS treatment.
Another factor that can contribute to low baseline muscle strength
is inﬂammation within the muscle, as seen in patients with
cachexia.54,55 Although HMB is known to downregulate muscle
inﬂammation,56e58 the possible decline in transport to themuscle due
to diminished nutritive ﬂow could also explain the low response to
EONS intervention in the severe sarcopenia subgroup.
Because this study was a nutrition-only trial without any exercise
intervention, no conclusive link can be drawn between the beneﬁts of
EONS and muscle blood ﬂow and/or muscle inﬂammation. Future
studies are needed to investigate the effects of including light resis-
tance and aerobic exercise to enhance nutritive ﬂow on the chronic
adaptations to ONS interventions. Additionally, because there were
many differences between ONS studied, no conclusions can be drawn
regarding beneﬁts of any individual or subgroup of macro- or
micronutrients.
J.T. Cramer et al. / JAMDA 17 (2016) 1044e10551054Despite the differential responses in leg strength and MQ observed
among sarcopenia subgroups, there was an increase in grip strength
over time in response to both ONS interventions (except in the sub-
group with normal grip strength). Similarly, there was an increase in
gait speed over time in all subgroups (except the group with normal
gait speed) in response to both ONS interventions. These overall
ﬁndings indicated that both ONS treatments (EONS and CONS) are
capable of eliciting clinical beneﬁts in simple ﬁeldmeasurements (grip
strength and gait speed) of sarcopenia in malnourished older adults.
In conclusion, the strengths of the current study include a well-
controlled, adequately powered, large sample, multicentered study
with multiple familiarization visits to minimize the learning effects
associated with effort-based outcome variables, such as leg strength,
grip strength, and gait speed. The present study demonstrated that
improvements in clinically relevant measures, such as strength and
functionality, can be achieved by daily supplementation with a high-
quality ONS. Furthermore, sarcopenia staging seems to affect the leg
strength adaptations to the ONS interventions, which supports the
incorporation of the EWGSOP conceptual framework of sarcopenia
staging into clinical practice. Populations with mild-moderate sarco-
penia are more responsive to the EONS enriched in key nutrients
compared with the standard CONS. Populations with severe sarcopenia
may need multimodal interventions (good nutrition and possibly
exercise) to achieve similar magnitudes of leg strength improvement
as the mild-moderate sarcopenia subgroups, particularly within a
limited time course. Therefore, sarcopenia staging should be consid-
ered in future intervention study designs.
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